Barclays PLC Grows Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Barclays PLC lifted its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 77.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 128,344 shares of the company’s stock after purchasing an additional 56,190 shares during the period. Barclays PLC’s holdings in Nurix Therapeutics were worth $2,884,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Amalgamated Bank boosted its stake in Nurix Therapeutics by 30.6% during the third quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock worth $49,000 after buying an additional 511 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Nurix Therapeutics by 31.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock valued at $54,000 after acquiring an additional 559 shares during the last quarter. Quest Partners LLC grew its holdings in shares of Nurix Therapeutics by 21.3% in the third quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock valued at $168,000 after purchasing an additional 1,312 shares during the period. ClariVest Asset Management LLC increased its position in Nurix Therapeutics by 2.9% during the second quarter. ClariVest Asset Management LLC now owns 63,149 shares of the company’s stock worth $1,318,000 after purchasing an additional 1,766 shares during the last quarter. Finally, Quarry LP increased its position in Nurix Therapeutics by 3,746.2% during the third quarter. Quarry LP now owns 2,500 shares of the company’s stock worth $56,000 after purchasing an additional 2,435 shares during the last quarter.

Nurix Therapeutics Price Performance

NRIX opened at $19.57 on Wednesday. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of -6.73 and a beta of 2.12. The business has a fifty day moving average price of $23.36 and a 200 day moving average price of $22.40. Nurix Therapeutics, Inc. has a 12 month low of $7.65 and a 12 month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings data on Friday, October 11th. The company reported ($0.67) EPS for the quarter, hitting analysts’ consensus estimates of ($0.67). The business had revenue of $12.59 million during the quarter, compared to the consensus estimate of $13.85 million. Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. On average, research analysts anticipate that Nurix Therapeutics, Inc. will post -2.81 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on NRIX. Jefferies Financial Group initiated coverage on shares of Nurix Therapeutics in a research note on Friday, October 11th. They issued a “buy” rating and a $41.00 price target for the company. Needham & Company LLC reiterated a “buy” rating and issued a $29.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, December 10th. UBS Group started coverage on Nurix Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $35.00 price target on the stock. Stephens reissued an “overweight” rating and set a $31.00 price objective on shares of Nurix Therapeutics in a research report on Monday, October 14th. Finally, Royal Bank of Canada decreased their target price on shares of Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating on the stock in a research report on Monday, October 14th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $30.35.

Insider Buying and Selling at Nurix Therapeutics

In related news, insider Gwenn Hansen sold 3,437 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $24.30, for a total value of $83,519.10. Following the completion of the transaction, the insider now directly owns 50,670 shares of the company’s stock, valued at $1,231,281. This represents a 6.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Houte Hans Van sold 2,368 shares of the stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total transaction of $57,542.40. Following the completion of the transaction, the chief financial officer now owns 37,270 shares in the company, valued at $905,661. This represents a 5.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 18,401 shares of company stock valued at $437,453. Insiders own 9.80% of the company’s stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.